Professor Piccart has a primary interest in breast cancer and drug development and is a leader in international research collaboration and the principal or co-principal investigator of many clinical trials, including HERA, MINDACT and ALTTO. She is co-founder and Chair of the Breast International Group (BIG), uniting 49 academic research groups from around the world and running over 30 trials under its umbrella.
BIG’s research programmes include the European Commission supported TRANSBIG consortium of 28 institutions in 11 countries (running with the EORTC the MINDACT trial) and NeoBIG, an innovative biomarker and drug development programme focused on neo-adjuvant trials.
Professor Piccart was President of ESMO (2012-2013) and ECCO (2014-2015). She is a member of the ESMO Magnitude of Clinical Benefit Scale Working Group and active in numerous professional organisations. She is a former president of EORTC and served on the ASCO Board. She is a member of the Belgian Royal Academy of Medicine and is a (co) author of more than 390 publications in peer-reviewed journals.